Less is More for TNFi Dosing in Axial Spondyloarthritis

February 4, 2019
Gregory M. Weiss, M.D.

Researchers writing in Arthritis Research and Therapy describe the results of a randomized clincal trial in which most patients with Ankylosing spondylitis maintained low disease activity or remission with standard or reduced TNFi dose schedules.

Researchers writing in Arthritis Research and Therapy describe the results of a randomized clincal trial in which most patients with Ankylosing spondylitis maintained low disease activity or remission with standard or reduced TNFi dose schedules.

References:

Jordi Gratacos, Caridad Pontes, Xavier Juanola, et al. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis. Arthritis Research & Therapy (2019) 21:11. https://doi.org/10.1186/s13075-018-1772-z